Beta Bionics

BBNX · NASDAQ

$17.74+$0.90 (+5.34%)TodayMarket closed · Oct 20, 4:35 PM ET

Prev close $16.84

About BBNX

Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.

Employees: 420
Headquarters: Irvine, California
Listed: Jan 30, 2025
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: betabionics.com

Leadership

Beta Bionics executives
Name	Title	Age
Adam Lezack	—	45
Sean Saint	—	49
Stephen Feider	—	35
Mark Hopman	—	47
Michael Mensinger	—	47
Steven Russell	—	56
Sean Carney	—	55
Dan Dearen	—	62
Christy Jones	—	55
Gerard Michel	—	60
Maria Palasis	—	60
Blake Beber	—	—

Similar companies

Companies in the same industry as Beta Bionics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.